Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Eculizumab - Alexion AstraZencea Rare Disease

Next Previous
X
Search
Drug Profile

Eculizumab - Alexion AstraZencea Rare Disease

Alternative Names: 5G1-1; 5G1.1; Anti-C5 monoclonal antibody 5G1-1; h5G1.1; Monoclonal antibody 5G1-1; Soliris

Latest Information Update: 16 May 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Alexion Pharmaceuticals
  • Developer Alexion AstraZeneca Rare Disease; Alexion Pharmaceuticals; Brigham and Womens Hospital; Handok Inc
  • Class Anti-inflammatories; Antiallergics; Antianaemics; Antiasthmatics; Antihypertensives; Antipsoriatics; Antirheumatics; Eye disorder therapies; Monoclonal antibodies; Neuroprotectants; Skin disorder therapies; Urologics
  • Mechanism of Action Complement C5 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Paroxysmal nocturnal haemoglobinuria; Delayed graft function; Neuromyelitis optica; Transplant rejection; Haemolytic uraemic syndrome; Myasthenia gravis; Dermatomyositis; Membranous glomerulonephritis
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Haemolytic uraemic syndrome; Myasthenia gravis; Neuromyelitis optica; Paroxysmal nocturnal haemoglobinuria
  • Phase III Delayed graft function; Guillain-Barre syndrome
  • Phase II Preeclampsia; Renal transplant rejection
  • No development reported Antiphospholipid syndrome; COVID-19 pneumonia; Heart transplant rejection; SARS-CoV-2 acute respiratory disease
  • Discontinued Adult respiratory distress syndrome; Age-related macular degeneration; Allergic asthma; Autoimmune haemolytic anaemia; Bullous pemphigoid; Dermatomyositis; Glomerulonephritis; Idiopathic thrombocytopenic purpura; Lupus nephritis; Membranous glomerulonephritis; Motor neuron disease; Psoriasis; Rheumatoid arthritis; Systemic lupus erythematosus

Most Recent Events

  • 03 May 2024 Alexion AstraZeneca Rare Disease terminates the phase II/III trial for Neuromyelitis optica (In children, In adolescents) in US, Canada, Germany, Italy, Japan, South Korea and Spain (IV) (NCT04155424)
  • 28 Mar 2024 No recent reports of development identified for clinical-Phase-Unknown development in COVID-19 pneumonia in France (IV)
  • 28 Mar 2024 No recent reports of development identified for clinical-Phase-Unknown development in COVID-19 pneumonia in USA (IV)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top